Jun 24, 2006
Hello, Why is it optimal to begin treatment when a patient "gets close" to Aids rather then when they have mild immune suppression? Secondly, at what situation (ie cd4 levels, etc)does it become dangerous/lifespan reducing to continue to live untreated? Thanks
Response from Dr. Young
Thanks for your post.
Let's start with your second question-- it's dangerous not to be on HIV treatment when CD4 counts are below 200. This is because when counts are below 200, there is a very real and increasing risk of developing AIDS complications. Many of these are life threatening conditions.
As for when is treatment optimal? This is an area of debate, subject largely to the benefit of treatment vs the risk (or costs) of treatments. Not everyone agrees on these points and each patient has a different set of conditions that impact this decision. In my opinion, if the patient is willing and able to be adherent to treatment, then I offer treatment earlier ("mild immune suppression") rather than later ("dangerous") . BY
Get Email Notifications When This Forum Updates or Subscribe With RSS
- Erectile Dysfunction After Receptive Anal Sex Without Condom Does It Mean I Have HIV
- Painful Urination After Oral Sex On A Woman What Are The Chances Of HIV
- Can An Sexually Transmitted Disease Cause White Vaginal Discharge?
- Can You Get Genital Warts From Sharing Razors Or Drinks?
- Bruise And Cut On Testicles And Hiv Transmission
- Getting Hiv From Blood On Clothes
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.